Abstract
Leishmaniasis is a spectrum of disease condition with considerable health impacts, caused by different species of Leishmania. This disease is currently endemic in 98 countries and territories in the world. There are many treatment modalities for cutaneous leishmaniasis. The use of topical terbinafine in the treatment of cutaneous leishmaniasis has recently been considered. Eighty-eight participants more than two years old with proven acute CL by a positive direct smear were randomly allocated to one of the two study arms: first group received meglumine antimoniate (Glucantime) 20 mg/kg/day intramuscular injection (IM) plus a placebo ointment (Mahan Vaseline) for 20 days. The second group received meglumine antimoniate (Glucantime) 20 mg/kg/day IM plus topical terbinafine, for 20 days and were monitored closely by dermatologist during the course of the study. Crude regression analysis showed that there was no significant difference between placebo and intervention group regarding partial or complete treatment (partial treatment: HRcrude = 1.1, CI 95 % = 0.7–1.7; complete treatment: HRcrude = 1.1, CI 95 % = 0.8–1.7). Although, there was no statistically significant different between the two treatment groups, but clinically it seems that the treatment rate in those who receive glucantime plus terbinafine was more effective than the other group. However this rate depended on the type of lesions. As data indicated ulcerated nodules, papules and plaque in experimental group have been completely improved two times faster than placebo group. Ulcerated nodules, nodules and plaque were partially improved faster in those used tebinafine than placebo ointment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aflatoonian MR, Sharifi I, Hakimi Parizi M, Aflatoonian B, Sharifi M, Khosravi A, Fekri AR, Khamesipour A, Sharifi H (2014) A prospective cohort study of cutaneous leishmaniasis risk and opium addiction in South Eastern Iran. PLoS ONE 9(2):e89043
Andrade-Neto VV, Cicco NN, Cunha-Junior EF, Canto-Cavalheiro MM, Atella GC, Torres-Santos EC (2011) The pharmacological inhibition of sterol biosynthesis in Leishmania is counteracted by enhancement of LDL endocytosis. Acta Trop 119(2–3):194–198
Bahadman KA, Tallab TM (1997) Terbinafin in the treatment of cutaneous leishmaniasis: a pilot study. Int J Dermatol 36:54–60
Bahashwan SA (2011) Therapeutic efficacy evaluation of metronidazole and some antifungal agents with meglumine antimoniate on visceral leishmaniasis by real-time light-cycler (LC) PCR in BALB/c mice. Trop J Pharm Res 10(3):255–263
Beach DH, Holtz CG, Anchlwe GE (1979) Eipid of leishmania promastigotes. Parasitol 65:203–216
Carstens J, Wendelboe P, Sogaard H, Thestrup-Pedersen K (1994) Toxic epidermal necrolysis follow therapy with terhinafine. Acta Derm Venereol (Stockh) 74:391–392
Ebrahimian S, Asilian A, Faghihi G (2011) A Comparative study on glucantime and oral terbinafine along with systemic glucantime on cutaneous leishmaniasis. J Isfahan Med Sch 28(118):1246–1252
Faergemann J (1997) Pharmacokinetics of terbinafine. Rev Contemp Pharmacother 8:289–297
Faergemann J, Zehender H, Jones T, Maibach I (1990) Terbinafine levels in serum, stratum corneum, dermis—epidermis (without stratum corneum), hair, sebum and eccrine sweat. Acta Derm Venereol (Stockh) 71:322–326
Gubta S, Jain VK, Aggarwal K (2005) Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis. Int J Dermatol 44:1064–1065
Kovacs MJ, Al-shammari S, Guenthor L, Bourcier M (1994) Neurotropenia and pancytopenia associated with oral terbinafine. Am Acad Dermatol 31:806
Lowe G, Geen C, Jennings R (1993) Hepatitis associated with terbinafine treatment. BMJ 306(6872):248
McGregor JM, Rustin MFL (1994) Terbinafine and erythema multiforme. Br J Dermatol 131:587–588
Najim RA, Sharquie KE, Farjou IB (1998) Zinc sulphate in the treatment of cutaneous leishmaniasis: an in vitro and animal study. Mem Inst Oswaldo Cruz 93:831–837
Ottervanger JP, Stroker BH (1992) Loss of taste and terbinafine. Lancet 340(8821):728
Ryder NS (1992) Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 39:2–7
Ryder NS, Mieth H (1992) Allylamine antifungal drugs. Curr Trop Med My Col 47:158–188
Sharifi I, Nakhaei N, Aflatoonian MR, Hakimi Parizi M, Fekri AR, Safizadeh H, Shirzadi MR, Gooya MM, Khamesipour A, Nadim A (2011) Cutaneous leishmaniasis in bam: a comparative evaluation of pre- and post-earthquake years (1999–2008). Iranian J Publ Health 40(2):49–56
Sharifi F, Sharifi I, Zarean M, Hakimi Parizi M, Aflatoonian MR, Fasihi Harandi M, Zahmatkesh R, Mashayekhi M, Kermanizadeh AR (2012) Spatial distribution and molecular identification of leishmania species from endemic foci of South-Eastern Iran. Iranian J Parasitol 7(1):45–52
Zakai HA, Zimoo SK (2002) Effect of itraconazole and terbinafine on Leishmania major promastigotes. J Kau Med Sci 10:73–80
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Farajzadeh, S., Heshmatkhah, A., Vares, B. et al. Topical terbinafine in the treatment of cutaneous leishmaniasis: triple blind randomized clinical trial. J Parasit Dis 40, 1159–1164 (2016). https://doi.org/10.1007/s12639-014-0641-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12639-014-0641-1